HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hirsch, I. B. Search for Related Content PubMed PubMed Citation Articles by Hirsch, I. B. Social Bookmarking                What's this?

Continuous Subcutaneous Insulin Infusion (CSII) of Insulin Aspart Versus Multiple Daily Injection of Insulin Aspart/Insulin Glargine in Type 1 Diabetic Patients Previously Treated With CSII

¹ University of Washington, Seattle, Washington
² Atlanta Diabetes Associates, Atlanta, Georgia
³ Barbara Davis Center for Childhood Diabetes, Denver, Colorado
⁴ Mountain Diabetes and Endocrine Center, Asheville, North Carolina
⁵ Rainier Clinical Research Center, Renton, Washington
⁶ Novo Nordisk Pharmaceuticals, Princeton, New Jersey
⁷ University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, New Brunswick, New Jersey

Address correspondence and reprint requests to Irl B. Hirsch, MD, University of Washington Medical Center, 1959 NE Pacific St., Box 356176, Seattle, WA 98195. E-mail: ihirsch{at}u.washington.edu

OBJECTIVE—Multiple daily injection (MDI) therapy of bolus insulin aspart and basal insulin glargine was compared with continuous subcutaneous insulin infusion (CSII) with aspart in type 1 diabetic patients previously treated with CSII.

RESEARCH DESIGN AND METHODS—One hundred patients were enrolled in a randomized, multicenter, open-label, crossover study. After a 1-week run-in period with aspart by CSII, 50 subjects were randomly assigned to MDI therapy (aspart immediately before each meal and glargine at bedtime) and 50 subjects continued CSII. After 5 weeks of the first treatment, subjects crossed over to the alternate treatment for 5 weeks. During the last week of each treatment period, subjects wore a continuous glucose monitoring system for 48–72 h.

RESULTS—Mean serum fructosamine levels were significantly lower after CSII therapy than after MDI therapy (343 ± 47 vs. 355 ± 50 µmol/l, respectively; P = 0.0001). Continuous glucose monitoring profiles over a 24-h time period showed that glucose exposure was 24 and 40% lower for CSII than MDI as measured by area under the curve (AUC) glucose 80 mg/dl (1,270 ± 742 vs. 1,664 ± 1,039 mg · h · dl^–1; P < 0.001) and AUC glucose 140 mg/dl (464 ± 452 vs. 777 ± 746 mg · h · dl^–1, CSII vs. MDI, respectively; P < 0.001). Similar percentages of subjects reported hypoglycemic episodes (CSII: 92%, MDI: 94%) and nocturnal (12:00 A.M. to 8:00 A.M.) hypoglycemic episodes (CSII: 73%, MDI: 72%). Major hypoglycemia was infrequent (CSII: two episodes, MDI: five episodes).

CONCLUSIONS—In a trial of short duration, CSII therapy with insulin aspart resulted in lower glycemic exposure without increased risk of hypoglycemia, as compared with MDI with insulin aspart and glargine.

Abbreviations: AUC, area under the curve • CGMS, continuous glucose monitoring system • CSII, continuous subcutaneous insulin infusion • MDI, multiple daily injection • SMBG, self-measured blood glucose

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S. A. Weinzimer, C. Ternand, C. Howard, C.-T. Chang, D. J. Becker, L. M.B. Laffel, and for the Insulin Aspart Pediatric Pump Study Group A Randomized Trial Comparing Continuous Subcutaneous Insulin Infusion of Insulin Aspart Versus Insulin Lispro in Children and Adolescents With Type 1 Diabetes Diabetes Care, February 1, 2008; 31(2): 210 - 215. [Abstract] [Full Text] [PDF]

				P. Rossetti, F. Porcellati, G. B. Bolli, and C. G. Fanelli Prevention of Hypoglycemia While Achieving Good Glycemic Control in Type 1 Diabetes: The role of insulin analogs Diabetes Care, February 1, 2008; 31(Supplement_2): S113 - S120. [Full Text] [PDF]

				J. C. Pickup and E. Renard Long-Acting Insulin Analogs Versus Insulin Pump Therapy for the Treatment of Type 1 and Type 2 Diabetes Diabetes Care, February 1, 2008; 31(Supplement_2): S140 - S145. [Abstract] [Full Text] [PDF]

				F. M Regan and D. B Dunger Use of new insulins in children Arch. Dis. Child. Ed. Pract., August 1, 2006; 91(2): ep47 - ep53. [Full Text] [PDF]

				J. C. Pickup Point: Are Insulin Pumps Underutilized in Type 1 Diabetes? Yes. Diabetes Care, June 1, 2006; 29(6): 1449 - 1452. [Full Text] [PDF]

				D. S. Schade and V. Valentine Counterpoint: Are Insulin Pumps Underutilized in Type 1 Diabetes? No. Diabetes Care, June 1, 2006; 29(6): 1453 - 1455. [Full Text] [PDF]

				B. Raju, A. M. Arbelaez, S. M. Breckenridge, and P. E. Cryer Nocturnal Hypoglycemia in Type 1 Diabetes: An Assessment of Preventive Bedtime Treatments J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2087 - 2092. [Abstract] [Full Text] [PDF]